Paxillin mutations, methods of assessing risk of metastasis and methods of staging tumors
OwnerRavi Salgiainventor
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for assessing risk of metastasis of a tumor in a mammal by determining the paxillin gene copy number per cell in the tumor or by detecting the presence of a paxillin mutation in the tumor. The presence of an increased paxillin gene copy number or a paxillin mutation is indicative of an increased risk of metastasis. Methods of staging tumors and methods of reducing invasiveness or metastasis of a cancer cell are also provided. Oligonucleotides comprising a paxillin mutation and antibodies capable of recognizing a paxillin mutant are disclosed.
Claims27
A method for assessing risk of metastasis of a tumor in a mammal, comprising determining the paxillin gene copy number or detecting the presence of a paxillin mutation in the tumor, the presence of an increased number of paxillin gene copies or a paxillin mutation being indicative of an increased risk of metastasis.
(canceled)
(canceled)
A method of staging a tumor in a mammal, comprising:
- (a) detecting the presence of a paxillin mutation in the tumor;
- and (b) correlating the presence of the paxillin mutation in the tumor with the stage of the tumor.
(canceled)
(canceled)
(canceled)
An isolated oligonucleotide at least 16 bases in length and comprising a paxillin mutation at a nucleotide of SEQ ID NO:36 selected from the group consisting of 162, 169, 191, 210, 211, 213, 214, 223, 224, 229, 388, 453, 489, 772, 788, 838, 902, 963, 1137, 1140, 1147, 1220, 1236, 1256, 1257, 1269, 1297, 1341, 1528, 1534, 1591, and 1601.
27-32. (canceled)
Dependencies are inferred from the claim text.